CURLF Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of -12.31% compared to Curaleaf Holdings's net margin of -49.65%. Curaleaf Holdings's return on equity of -17.61% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Curaleaf Holdings has a consensus price target of --, signalling upside risk potential of 336.24%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 602.96%. Given that NovaBay Pharmaceuticals has higher upside potential than Curaleaf Holdings, analysts believe NovaBay Pharmaceuticals is more attractive than Curaleaf Holdings.

Curaleaf Holdings has a beta of 1.203, which suggesting that the stock is 20.335% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.383%.

Curaleaf Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Curaleaf Holdings pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Curaleaf Holdings quarterly revenues are $330.5M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Curaleaf Holdings's net income of -$40.7M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Curaleaf Holdings's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Curaleaf Holdings is 0.81x versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Poseida Therapeutics has a net margin of -12.31% compared to Curaleaf Holdings's net margin of 28.2%. Curaleaf Holdings's return on equity of -17.61% beat Poseida Therapeutics's return on equity of -66.05%.

Curaleaf Holdings has a consensus price target of --, signalling upside risk potential of 336.24%. On the other hand Poseida Therapeutics has an analysts' consensus of $14.00 which suggests that it could grow by 0.32%. Given that Curaleaf Holdings has higher upside potential than Poseida Therapeutics, analysts believe Curaleaf Holdings is more attractive than Poseida Therapeutics.

Curaleaf Holdings has a beta of 1.203, which suggesting that the stock is 20.335% more volatile than S&P 500. In comparison Poseida Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Curaleaf Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Poseida Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Curaleaf Holdings pays -- of its earnings as a dividend. Poseida Therapeutics pays out -- of its earnings as a dividend.

Curaleaf Holdings quarterly revenues are $330.5M, which are larger than Poseida Therapeutics quarterly revenues of $71.7M. Curaleaf Holdings's net income of -$40.7M is lower than Poseida Therapeutics's net income of $20.2M. Notably, Curaleaf Holdings's price-to-earnings ratio is -- while Poseida Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Curaleaf Holdings is 0.81x versus 6.07x for Poseida Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -12.31% compared to Curaleaf Holdings's net margin of -2357.27%. Curaleaf Holdings's return on equity of -17.61% beat Palatin Technologies's return on equity of --.

Curaleaf Holdings has a consensus price target of --, signalling upside risk potential of 336.24%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1656.38%. Given that Palatin Technologies has higher upside potential than Curaleaf Holdings, analysts believe Palatin Technologies is more attractive than Curaleaf Holdings.

Curaleaf Holdings has a beta of 1.203, which suggesting that the stock is 20.335% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.9%.

Curaleaf Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Curaleaf Holdings pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Curaleaf Holdings quarterly revenues are $330.5M, which are larger than Palatin Technologies quarterly revenues of $350K. Curaleaf Holdings's net income of -$40.7M is lower than Palatin Technologies's net income of -$7.8M. Notably, Curaleaf Holdings's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Curaleaf Holdings is 0.81x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Sage Therapeutics has a net margin of -12.31% compared to Curaleaf Holdings's net margin of -788.06%. Curaleaf Holdings's return on equity of -17.61% beat Sage Therapeutics's return on equity of -48.2%.

Curaleaf Holdings has a consensus price target of --, signalling upside risk potential of 336.24%. On the other hand Sage Therapeutics has an analysts' consensus of $24.39 which suggests that it could grow by 60.43%. Given that Curaleaf Holdings has higher upside potential than Sage Therapeutics, analysts believe Curaleaf Holdings is more attractive than Sage Therapeutics.

Curaleaf Holdings has a beta of 1.203, which suggesting that the stock is 20.335% more volatile than S&P 500. In comparison Sage Therapeutics has a beta of 0.869, suggesting its less volatile than the S&P 500 by 13.067%.

Curaleaf Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sage Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Curaleaf Holdings pays -- of its earnings as a dividend. Sage Therapeutics pays out -- of its earnings as a dividend.

Curaleaf Holdings quarterly revenues are $330.5M, which are larger than Sage Therapeutics quarterly revenues of $11.9M. Curaleaf Holdings's net income of -$40.7M is higher than Sage Therapeutics's net income of -$93.6M. Notably, Curaleaf Holdings's price-to-earnings ratio is -- while Sage Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Curaleaf Holdings is 0.81x versus 3.19x for Sage Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.